Figure 1.
CaMKIIα inhibition by prophylactic KN93 administration reduced clinical symptoms and attenuated hyperalgesia in EAE. Separate groups of eight mice were treated with KN93 (45 nmol, i.t.) or saline from Day 1 to Day 8 along with the immunization with MOG35-55 on Day 0 to induce EAE. A–D, Prophylactic KN93 administration (45 nmol, i.t.) significantly attenuated clinical symptoms (A), locomotor impairment (B), mechanical allodynia (C), and thermal hyperalgesia (D). Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the sham immune group; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with the saline-treated EAE group.